These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1588922)

  • 21. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.
    Stock N; Baccei C; Bain G; Broadhead A; Chapman C; Darlington J; King C; Lee C; Li Y; Lorrain DS; Prodanovich P; Rong H; Santini A; Zunic J; Evans JF; Hutchinson JH; Prasit P
    Bioorg Med Chem Lett; 2010 Jan; 20(1):213-7. PubMed ID: 19914828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of radiolabeled high affinity antagonist to leukotriene D4 receptor in guinea pig lung membranes: interconversion of agonist-receptor binding affinity states.
    O'Sullivan BP; Mong S
    Mol Pharmacol; 1989 Jun; 35(6):795-802. PubMed ID: 2543913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.
    Mancini JA; Coppolino MG; Klassen JH; Charleson S; Vickers PJ
    Life Sci; 1994; 54(9):PL137-42. PubMed ID: 8114608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.
    Tagari P; Becker A; Brideau C; Frenette R; Sadl V; Thomas E; Vickers P; Ford-Hutchinson A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):416-25. PubMed ID: 8386242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
    Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
    J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-species comparison of 5-lipoxygenase-activating protein.
    Vickers PJ; O'Neill GP; Mancini JA; Charleson S; Abramovitz M
    Mol Pharmacol; 1992 Dec; 42(6):1014-9. PubMed ID: 1480129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
    Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
    Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells.
    Goppelt-Struebe M; Schaefer D; Habenicht AJ
    Br J Pharmacol; 1997 Oct; 122(4):619-24. PubMed ID: 9375956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
    Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and characterization of a high affinity radioiodinated probe for the alpha 2-adrenergic receptor.
    Lanier SM; Hess HJ; Grodski A; Graham RM; Homcy CJ
    Mol Pharmacol; 1986 Mar; 29(3):219-27. PubMed ID: 3005829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoxygenase metabolism is required for interleukin-3 dependent proliferation and cell cycle progression of the human M-07e cell line.
    Miller AM; Allen BS; Ziboh V
    J Cell Physiol; 1997 Mar; 170(3):309-15. PubMed ID: 9066788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
    Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
    Müller-Peddinghaus R
    J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein.
    Strid T; Svartz J; Franck N; Hallin E; Ingelsson B; Söderström M; Hammarström S
    Biochem Biophys Res Commun; 2009 Apr; 381(4):518-22. PubMed ID: 19233132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.
    Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL
    Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.
    Maxis K; Delalandre A; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D
    Arthritis Res Ther; 2006; 8(6):R181. PubMed ID: 17156456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes.
    Gerstmeier J; Weinigel C; Rummler S; Rådmark O; Werz O; Garscha U
    FASEB J; 2016 Jan; 30(1):276-85. PubMed ID: 26396238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of the production and action of leukotrienes by MK-571 and MK-886.
    Ford-Hutchinson AW
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():9-16. PubMed ID: 1847788
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of novel leukotriene--based anti-asthma drugs: MK-886 and MK-571.
    Young RN
    Agents Actions Suppl; 1991; 34():179-87. PubMed ID: 1793062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP.
    Datta K; Biswal SS; Kehrer JP
    Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):371-5. PubMed ID: 10333477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.